Leadership Transition at Volpara Health
Volpara Health, a frontrunner in AI-powered breast health solutions, has announced significant leadership changes. Craig Hadfield, previously the Chief Customer and Financial Officer, is stepping into the role of CEO, succeeding Teri Thomas. This transition comes as Thomas pursues new opportunities after successfully leading the company for several years.
Craig Hadfield Takes the Helm
Hadfield's extensive experience with Volpara has made him a pivotal figure in the company's growth trajectory. Under Teri Thomas's leadership, the company enjoyed remarkable financial success, increasing annual recurring revenue to over $34 million. The transition signifies a continuing commitment to innovation and enhanced customer service at Volpara.
Reflecting on her time at Volpara, Teri Thomas expressed pride in the company's achievements and a positive outlook for the future. The company’s advancements in AI technology have not only transformed the platform but have also solidified its standing in the breast health landscape.
Significant Milestone: BOADICEA Integration
Another remarkable announcement is the integration of Volpara's volumetric breast density assessment into the BOADICEA breast cancer risk model. This integration not only positions Volpara at the forefront of breast cancer metrics but also enhances the accuracy of risk assessments for healthcare providers.
Enhanced Accuracy in Risk Assessment
The use of Volpara density in the BOADICEA model has shown improved accuracy over traditional BI-RADS density categories. This development allows physicians to provide more accurate risk assessments to their patients, facilitating better-informed healthcare decisions.
Volpara density is now incorporated into two core breast cancer risk models recognized in NCCN guidelines – BOADICEA and Tyrer-Cuzick. This change underscores Volpara's commitment to driving more effective healthcare solutions and its role in international breast health practices.
Record-Breaking Research Presence at ECR 2025
Volpara Health and its partner, Lunit, are also making waves with an impressive lineup of research studies presented at ECR 2025. A record of 21 independent research abstracts featuring both companies' innovative solutions showcases the growing impact of AI technologies in cancer detection and treatment.
Advancements in AI and Radiology
This achievement reflects the increasing acknowledgment of AI-driven solutions within the radiology community. The showcased research highlights how Volpara and Lunit are dedicated to pushing the boundaries of technology in cancer care and enhancing patient outcomes through advanced scientific findings.
About Volpara Health
Volpara Health is on a mission to revolutionize the fight against cancer. With AI-driven software, they assist healthcare providers in understanding cancer risks and developing personalized treatment plans. The technology is utilized in over 3,500 facilities and impacts nearly 18 million patients, supporting over 3.6 million cancer risk assessments annually.
With a robust integration system for electronic health records and imaging systems, Volpara ensures seamless operation that enhances compliance and accreditation for healthcare providers. Based in Wellington, New Zealand, with an office in Seattle, Volpara stands out as a trusted partner for healthcare institutions worldwide.
Frequently Asked Questions
What leadership changes are happening at Volpara Health?
The new CEO, Craig Hadfield, is succeeding Teri Thomas, who played a crucial role in the company's growth.
How is Volpara Health contributing to cancer risk assessment?
Volpara's volumetric breast density is now integrated into the BOADICEA breast cancer risk model, enhancing accuracy in risk assessments.
What is the significance of ECR 2025 for Volpara Health?
At ECR 2025, Volpara and Lunit have showcased a record number of independent research abstracts, illustrating their commitment to advancing breast health solutions.
Where is Volpara Health headquartered?
Volpara Health is headquartered in Wellington, New Zealand, with an additional office in Seattle.
How many patients does Volpara Health impact?
Volpara's solutions impact nearly 18 million patients and support millions of annual cancer risk assessments.
